ABUS
(NASDAQ)
1.03
-0.0079  (-0.77%)
Volume (24h): 433.84K Day Range: 0.9900 - 1.10
Market Cap: 71.86M 52W Range: 0.8241 - 4.56
Mar-31-20 12:47PM Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?Zacks
10:16AM The Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Have Been Trimming Their Sales ForecastsSimply Wall St.
Mar-27-20 12:02PM The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends GuidanceBenzinga
Mar-26-20 08:05PM Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis BGlobeNewswire
Mar-05-20 01:55PM Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue EstimatesZacks
12:30PM Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline UpdateGlobeNewswire
Feb-27-20 05:30PM Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks
01:00PM Arbutus to Report Fourth Quarter and Year-End 2019 Financial ResultsGlobeNewswire
Feb-10-20 01:00PM Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-DestabilizerGlobeNewswire
Jan-02-20 10:05AM Does The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Price Tend To Follow The Market?Simply Wall St.
Dec-30-19 03:08PM Options Traders Expect Huge Moves in Arbutus Biopharma (ABUS) StockZacks
Dec-27-19 02:04PM Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock DownZacks
Dec-19-19 08:50PM Arbutus Biopharma Corp (ABUS): Hedge Funds In Wait-and-See ModeInsider Monkey
Nov-06-19 02:35PM Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue EstimatesZacks
12:30PM Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
Nov-03-19 12:13PM We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn RateSimply Wall St.
Oct-30-19 02:33PM Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should KnowZacks
11:30AM Arbutus to Report Third Quarter 2019 Financial ResultsGlobeNewswire
Oct-10-19 06:59PM Bucks biopharm firm halts study of potential hepatitis B cureAmerican City Business Journals
Oct-04-19 11:32AM The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid OfferingBenzinga
Oct-03-19 08:05PM Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis BGlobeNewswire
Sep-26-19 11:30AM Arbutus to Participate in Upcoming Investor ConferencesGlobeNewswire
Sep-19-19 10:17AM Did You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop?Simply Wall St.
Aug-20-19 08:05PM Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of DirectorsGlobeNewswire
Aug-06-19 11:30AM Arbutus to Participate at Wedbush PacGrow Healthcare ConferenceGlobeNewswire
Aug-05-19 12:55PM Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue EstimatesZacks
11:30AM Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
Jul-29-19 11:30AM Arbutus to Report Second Quarter 2019 Financial ResultsGlobeNewswire
Jul-25-19 02:34PM Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should KnowZacks
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)